Lecture image placeholder

Premium content

Access to this content requires a subscription. You must be a premium user to view this content.

Monthly subscription - $9.99Pay per view - $4.99Access through your institutionLogin with Underline account
Need help?
Contact us
Lecture placeholder background
VIDEO DOI: https://doi.org/10.48448/ak26-tc09

technical paper

ENDO 2022

July 11, 2022

Atlanta, United States

Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus

Please log in to leave a comment

Downloads

Transcript English (automatic)

Next from ENDO 2022

Impact of Continuous Glucose Monitoring (CGM) on Lifestyle Modifications in Individuals with Prediabetes
technical paper

Impact of Continuous Glucose Monitoring (CGM) on Lifestyle Modifications in Individuals with Prediabetes

ENDO 2022

Hisham Frahan

11 July 2022

Similar lecture

Expression of the Neuropeptide Substance P and the NK1 Receptor in Aldosterone-Producing Adenomas
technical paper

Expression of the Neuropeptide Substance P and the NK1 Receptor in Aldosterone-Producing Adenomas

ENDO 2022

Antoine-Guy Lopez

11 July 2022

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Lectures
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2023 Underline - All rights reserved